Detalhe da pesquisa
1.
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma.
Blood
; 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38728430
2.
Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial.
Blood
; 141(14): 1666-1674, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36564045
3.
Chromothripsis as a pathogenic driver of multiple myeloma.
Semin Cell Dev Biol
; 123: 115-123, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33958284
4.
Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.
Eur J Haematol
; 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38654611
5.
Endogenous epitope tagging of eEF1A2 in mice reveals early embryonic expression of eEF1A2 and subcellular compartmentalisation of neuronal eEF1A1 and eEF1A2.
Mol Cell Neurosci
; 126: 103879, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37429391
6.
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial.
Br J Haematol
; 201(2): 267-279, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36541152
7.
Recapitulation of the EEF1A2 D252H neurodevelopmental disorder-causing missense mutation in mice reveals a toxic gain of function.
Hum Mol Genet
; 29(10): 1592-1606, 2020 06 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32160274
8.
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
Blood
; 136(9): 1091-1104, 2020 08 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32438407
9.
Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial.
Haematologica
; 107(1): 231-242, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33297668
10.
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
Lancet Oncol
; 22(3): e105-e118, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33662288
11.
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
PLoS Med
; 18(1): e1003454, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33428632
12.
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma.
Br J Haematol
; 193(3): 551-555, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32524584
13.
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial.
Br J Haematol
; 192(5): 853-868, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32656799
14.
Toward personalized treatment in multiple myeloma based on molecular characteristics.
Blood
; 133(7): 660-675, 2019 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30587529
15.
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive).
Haematologica
; 106(10): 2694-2706, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33910333
16.
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
Haematologica
; 106(7): 1957-1967, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32499244
17.
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
Ann Hematol
; 100(9): 2325-2337, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-33970288
18.
Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA.
Eur J Haematol
; 106(2): 230-240, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33107092
19.
Retraction: Ku86 Variant Expression and Function in Multiple Myeloma Cells Is Associated with Increased Sensitivity to DNA Damage.
J Immunol
; 212(8): 1392, 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38416013
20.
Management of patients with difficult-to-treat multiple myeloma.
Future Oncol
; 17(16): 2089-2105, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33706558